Search results for "Acute Disease"

showing 10 items of 430 documents

Steroid and vasoactive treatment for acute deafness after attempted hearing preservation acoustic neuroma surgery.

2004

<i>Objective:</i> To investigate whether intravenous steroid and vasoactive therapy in the acute postoperative period improves hearing outcome in patients who develop acute deafness after attempted hearing preservation surgery for acoustic neuroma (AN) through a retrosigmoid or a middle cranial fossa approach. <i>Study Design and Setting:</i> Retrospective controlled study in a tertiary care center. Thirty-six patients who had developed acute deafness after hearing preservation surgery for treatment of an AN were reviewed. Preoperative AAOHNS hearing class was A in 2, B in 2 and D in 32 patients. Twenty-seven patients were treated with prednisolone, hydroxyethyl star…

medicine.medical_specialtymedicine.drug_classHearing lossmedicine.medical_treatmentPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsAcoustic neuromaDeafnessHydroxyethyl Starch DerivativesPostoperative ComplicationsAcoustic neuroma surgeryVasoactiveotorhinolaryngologic diseasesmedicineEvoked Potentials Auditory Brain StemHumansIn patientPentoxifyllineRetrospective StudiesSalvage TherapyHearing preservationChemotherapybusiness.industryNeuroma Acousticmedicine.diseaseSurgeryOtorhinolaryngologyAnesthesiaAcute DiseaseInjections IntravenousCorticosteroidDrug Therapy Combinationmedicine.symptombusinessORL; journal for oto-rhino-laryngology and its related specialties
researchProduct

Early Spot Urinary Sodium and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction

2020

<b><i>Objective:</i></b> In acute heart failure (AHF), early assessment of spot urinary sodium (U<sub>Na</sub>) has emerged as a useful biomarker for risk stratification and monitoring. The objective of this study was to investigate (a) whether early spot U<sub>Na</sub> predicts 24-h diuretic efficiency and (b) the clinical factors associated with early spot U<sub>Na</sub> in patients with AHF and concomitant renal dysfunction (RD). <b><i>Methods:</i></b> This is a post hoc analysis of the IMPROVE-HF trial, in which 160 patients with AHF and RD (estimated glomerular filtrate rate [eGFR] <60 mL/min/1…

medicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmentUrologyInterquartile rangePost-hoc analysismedicineNatriuretic peptideHumansDiureticsAgedAged 80 and overHeart Failurebusiness.industrySodiumFurosemidemedicine.diseaseHeart failureConcomitantAcute DiseasePopulation studyKidney DiseasesDiureticCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiorenal Medicine
researchProduct

Alteration of the Calcium Content in Inner Hair Cells of the Cochlea of the Guinea Pig after Acute Noise Trauma with and without Application of the O…

1999

Calcium ions are known to be important to the process of signal transduction across the apical and basal sides of the inner hair cells. Calcium channel antagonists have been demonstrated by light microscopy to provide protection against acoustic trauma. To evaluate the protective effect of calcium channel blocker on the inner ear cells to noise exposure, the amount of the histochemical reaction products formed in the cytoplasm of the inner hair cells of the guinea pig after application of pyroantimonate was measured by an image processing system connected to an energy-filtering transmission electron microscope (EFTEM). Compared to untreated control specimens (experimental animal group I) th…

medicine.medical_specialtymedicine.drug_classchemistry.chemical_elementCalcium channel blockerCalciumDiltiazemInternal medicineotorhinolaryngologic diseasesmedicineAnimalsInner earDiltiazemCochleaHair Cells Auditory InnerCalcium channelCalcium Channel BlockersDisease Models AnimalEndocrinologymedicine.anatomical_structureHearing Loss Noise-InducedOtorhinolaryngologychemistryCytoplasmAcute DiseaseCalciumsense organsHair cellmedicine.drugORL
researchProduct

Prevention of early complications and late consequences after acute pulmonary embolism: Focus on reperfusion techniques

2017

Pulmonary embolism (PE) is a major cause of acute cardiovascular mortality and long-term morbidity. Right ventricular (RV) dysfunction is the key determinant of prognosis in the acute phase of PE, and residual RV dysfunction is associated with the development of post-PE functional impairment, chronic thromboembolic disease, and higher costs of treatment over the long term. Patients with clinically overt RV failure, i.e. hemodynamic collapse at presentation (high-risk PE), necessitate immediate thrombolytic treatment to relieve the obstruction in the pulmonary circulation; surgical or catheter-directed removal of the thrombus can be an alternative option. For patients with a high risk of ble…

medicine.medical_specialtymedicine.medical_treatmentHemodynamics030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansThrombolytic TherapyThromboembolic diseaseDecompensation030212 general & internal medicineThrombusIntensive care medicineCardiovascular mortalitybusiness.industryHematologyHeparinThrombolysisPrognosismedicine.diseasePulmonary embolismTreatment OutcomeAcute DiseaseReperfusionCardiologyPulmonary Embolismbusinessmedicine.drugThrombosis Research
researchProduct

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct

Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

2017

Abstract Introduction and objectives The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1. Methods Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4 mg/dL on admission will be randomized to: a) standard diuretic str…

medicine.medical_specialtymedicine.medical_treatmentWater-Electrolyte ImbalanceRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyPatient Care Planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFurosemideInternal medicineHumansMedicine030212 general & internal medicineDiureticsIntensive care medicineHeart FailureCreatinineCardio-Renal Syndromebusiness.industryClinical study designChlorthalidoneMembrane ProteinsGeneral Medicinemedicine.diseasePathophysiologyAcetazolamideClinical trialchemistryCA-125 AntigenCreatinineHeart failureAcute DiseaseCardiologyDiureticbusinessRevista Española de Cardiología (English Edition)
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

INFLAMMATORY CYTOKINES IN ACUTE ISCHEMIC STROKE.

2008

Three major cytokines, namely, tumor necrosis factor (TNF-alpha), interleukin (IL)-1, and IL-6 are produced by cultured brain cells after various stimuli such as ischemia. Neurones, astrocytes, microglia and oligodendrocytes can produce inflammatory mediators, and cytokine receptors are expressed constitutionally throughout the Central Nervous System (CNS), albeit at low levels. Cytokines are involved in virtually every facet of stroke and they have numerous pro-inflammatory and pro-coagulant effects on endothelium. TNF-alpha expression after stroke stimulates expression of tissue factor and adhesion molecules for leukocytes, release of interleukin-1 (IL-1), nitric oxide, factor VIII/von Wi…

medicine.medical_treatmentInflammationProinflammatory cytokineBrain IschemiaBrain ischemiaTissue factorDrug DiscoverymedicineHumansStrokePharmacologyInflammationMicrogliabusiness.industrymedicine.diseasePrognosisStrokeCytokinemedicine.anatomical_structureImmunologyAcute DiseaseCytokinesTumor necrosis factor alphamedicine.symptomStroke cytokinesbusinessBiomarkers
researchProduct

Interaction Between Cytokines and Oxidative Stress in Acute Pancreatitis

2006

Acute pancreatitis is an inflammation initially localized in the pancreatic gland which may lead to local and systemic complications. The development of severe acute pancreatitis is mediated by pathophysiological mechanisms involved in the systemic inflammatory response, cytokines and oxidative stress being their components of major importance. Nevertheless, it is still unknown why an episode of acute pancreatitis remains mild or progresses to a severe form. Activated leukocytes are the main source of cytokines. Interleukin 1beta and tumor necrosis factor alpha (TNF-alpha) initiate and propagate almost all the consequences of the systemic inflammatory response syndrome, leading to amplifica…

medicine.medical_treatmentInflammationmedicine.disease_causeBiochemistryProinflammatory cytokineDrug DiscoverymedicineAnimalsHumansPharmacologyChemistryOrganic ChemistryModels Immunologicalmedicine.diseaseSystemic inflammatory response syndromeOxidative StressCytokinePancreatitisAcute DiseaseImmunologyCytokinesMolecular MedicineAcute pancreatitisPancreatitisTumor necrosis factor alphamedicine.symptomOxidative stressCurrent Medicinal Chemistry
researchProduct

Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis.

2003

Inflammation underlies both onset and perpetuation of atherosclerosis. Plasma lipoproteins transport the platelet-activating factor-acetylhydrolase (PAF-AH) with potentially anti-inflammatory activities. Our aim was to determine whether PAF-AH activity was associated with inflammatory markers and with coronary artery disease (CAD). PAF-AH activity and a panel of inflammatory mediators were measured in plasma of 496 patients with CAD and in 477 controls; 276 patients presented with stable angina pectoris and 220 with acute coronary syndrome (ACS). Individuals within the highest quartile of PAF-AH activity had an 1.8-fold increase in CAD risk [95% confidence interval (CI), 1.01 to 3.2; P = 0.…

platelet-activating factorAdultMaleRiskmedicine.medical_specialtyAcute coronary syndromePAF acetylhydrolaseStatinCross-sectional studymedicine.drug_classMutation MissenseInflammationAngiotensin-Converting Enzyme InhibitorsQD415-436Coronary Artery DiseaseBiochemistryCoronary artery diseaseEndocrinologySex FactorsRisk FactorsInternal medicinemedicineHumansAgedInflammationbusiness.industryCell BiologySyndromeMiddle Agedmedicine.diseaseConfidence intervalCross-Sectional StudiesQuartile1-Alkyl-2-acetylglycerophosphocholine EsteraseAcute DiseaseCardiologylipids (amino acids peptides and proteins)Femaleatherosclerosismedicine.symptombusinessJournal of lipid research
researchProduct